Open Orphan expands volunteer recruitment centres for human challenge trials

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and the world leader in vaccine and antiviral testing using human challenge clinical trials, has opened two new volunteer recruitment centres to screen potential trial volunteers, the first in East London and a second in central Manchester. These new locations are part of the Company’s expansion of its human challenge study trials launching in 2021.

The first new site is a repurposed former coffee shop at the street level of Queen Mary BioEnterprise Innovation Centre (“QMB”), which houses hVIVO’s current 24-bedroom state-of-the-art quarantine clinic in Whitechapel, East London. This is the first time a branded volunteer recruitment centre  has been situated at street level whereby volunteers can walk straight in for screening. The large, multi-use space has the capacity to provide substantially more volunteer medical screening and processing with dedicated private physical exam and consenting rooms, ample hot-desking space and a refreshment area, as well as a dedicated reception area. Importantly, this means the facility can now offer 520 volunteer recruitment visit slots per week, with the intention that this will increase over time. This new centre has processed its first volunteers in recent weeks. Learn more about the screening process at www.flucamp.com/what-is-screening/.

The Company has opened another similar volunteer recruitment facility in central Manchester, broadening its reach and reducing travel time required by potential volunteers to attend the initial visit at our London clinic. It will have an initial capacity for more than 100 visits per week, but this will increase substantially in the weeks that follow. The clinic is due to process its first volunteers on 27 January.

Cathal Friel, Executive Chairman of Open Orphan plc commented: “We are delighted to have had the opportunity to get access to these new volunteer recruitment screening centres and to have them fully operational so quickly. The current pandemic has forced many businesses to close and we are able to provide another use for these spaces not currently in use. These spaces presented an opportunity for us to open street level volunteer recruitment centres quickly and efficiently. The number of volunteers required by hVIVO is increasing rapidly in line with the number of studies the company is running, and these two additional centres will allow us to increase our capacity substantially in the year ahead. Given our extensive pipeline of upcoming contracted studies, we are also continuing to explore additional quarantine facilities.  

We are proud of our hard working and dedicated team for transforming both of these sites in record time into volunteer recruitment screening centres where we can efficiently process more volunteers than ever before.”

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. hVIVO welcomes volunteers to take part in our clinical trials under expertly supervised conditions, to further medical research, and help us to take the understanding of respiratory illnesses to a new level. Volunteers are central to the work that we do; our studies focus on testing new treatments on real people, in a safe, controlled, clinical environment.

Further details on all aspects of our volunteer programs including testimonials from previous volunteers can be found at www.flucamp.com.

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan appoints Yamin ‘Mo’ Khan as Chief Executive Officer

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announced today the appointment of Yamin ‘Mo’ Khan as Chief Executive Officer

Open Orphan Plc

Potential RSV vaccine achieves regulatory step in US

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for a vaccine candidate for respiratory syncytial virus (RSV). Bavarian Nordic’s MVA-BN RSV was granted the designation, which is designed to expedite the development

Open Orphan Plc

Open Orphan FDA Breakthrough Designation for Big Pharma RSV candidate

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, noted today the announcement dated 14 February 2022 from Bavarian Nordic A/S (OMX: BAVA), reporting

Open Orphan Plc

The Drug development plan – Your roadmap to success

Each journey begins at a starting point, and we believe that few journeys are as exciting as developing a drug. In order to succeed and reach your destination, you need a solid roadmap, the drug development

Open Orphan Plc

Open Orphan launch STRiVE project a remarkable success

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has recently launched

Open Orphan Plc

What is malaria?

Malaria is often quoted as the most common disease in all human history. With the earliest recorded cases are estimated to have been around 10,000 years ago, when a small plasmodium parasite made a jump across

Open Orphan Plc

Omicron and Long COVID: What we know so far

As the Omicron variant of the coronavirus continues to sweep across the United States, another important question has emerged for scientists worldwide: Will more transmission equal more long COVID cases? The rate of hospitalization has also

Open Orphan Plc

Pharmacokinetics Course

Pharmacokinetics (PK) is generally referred to as ‘what the body does to the drug’ versus ‘what the drug does to the body’ (pharmacodynamics [PD]). Pharmacokinetics describes the fate, or time course, of an administered drug within

Open Orphan Plc

Open Orphan launch new malaria human challenge

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials announces that further to the announcement on 9 August 2021, hVIVO, a subsidiary

Open Orphan Plc

RSV vaccines & treatments

The Challenge Respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract infection (LRTI) in infants and young children worldwide and can cause LRTI in elderly and immunocompromised patients; it is associated

Open Orphan Plc

FluCamp 2021 Year in Review

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO